
Annovis Bio, Inc. (ANVS) Stock Ticker
ANVS right now
Market factors today
Unlock the full ANVS picture
About Annovis Bio, Inc.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
ANVS stock facts
| Ticker symbol | ANVS |
| Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $55.7M |
| CEO | Maria L. Maccecchini |
| Employees | 7 |
| Headquarters | Malvern, PA, US |
| IPO date | 2020-01-29 |
| Website | www.annovisbio.com |
What you can see for ANVS on Tickr
Live ANVS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ANVS report.
Rankings
FAQ
What is the ticker symbol for Annovis Bio, Inc.?
The ticker symbol for Annovis Bio, Inc. is ANVS, listed on the New York Stock Exchange.
What is ANVS?
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals…